The characterization of the CD38 protein and its overexpression on myeloma cells has resulted in the development of monoclonal antibodies (mAbs) targeting CD38, of which two antibodies—daratumumab and isatuximab—have been approved for clinical use.2, 5, 6, 7, 8, 9, 10. Here, CD38 is linked to plasma cell myeloma.